Novartis paid $650 million for the overseas use of the anti-PD-1 drug tislezumab

Novartis announced Monday that it has signed a strategic agreement with Baiji Shenzhou to sell Tislelizumab in several major markets outside China.
as part of the deal, Novarma will make an upfront cash payment of $650 million to Baxer, which is also expected to receive up to $1.3 billion in cash payments after reaching regulatory milestones.
specifically, the agreement gives Novartis the right to develop and market Tislelizumab in the United States, the European Union, the United Kingdom, Norway, Switzerland, Iceland, Liechtenstein, Russia and Japan.
, Baiji Shenzhou will retain the development and marketing rights of tislezumab in China.
also filed an application seeking approval from Chinese regulators for the drug for advanced squamous and non-squamous non-small cell lung cancer (NSCLC) and non-removable hepatocellular carcinoma (HCC).
Novartis and Baiji Shenzhou said they had evaluated Tislelizumab in 15 clinical trials involving more than 7,700 patients with various tumors, including NSCLC, HCC, esopausal squamous cell carcinoma, stomach cancer and nasopharyngeal cancer, and expected to file regulatory documents for the first time outside China in 2021.